S&P 500   3,692.39 (+0.70%)
DOW   30,165.19 (+0.65%)
QQQ   304.95 (+0.22%)
AAPL   121.97 (-0.79%)
MSFT   213.55 (-0.32%)
FB   279.87 (-0.70%)
GOOGL   1,822.78 (+0.05%)
AMZN   3,163.44 (-0.73%)
TSLA   594.78 (+0.24%)
NVDA   539.33 (+0.65%)
BABA   267.61 (+0.26%)
CGC   28.65 (+0.07%)
GE   10.79 (+1.79%)
MU   73.05 (+4.51%)
AMD   93.92 (+1.74%)
T   29.46 (+0.79%)
NIO   42.81 (-5.60%)
F   9.32 (+1.19%)
ACB   10.92 (-2.85%)
BA   232.36 (-2.04%)
NFLX   498.78 (+0.25%)
GILD   61.44 (+0.95%)
DIS   153.83 (+0.39%)
S&P 500   3,692.39 (+0.70%)
DOW   30,165.19 (+0.65%)
QQQ   304.95 (+0.22%)
AAPL   121.97 (-0.79%)
MSFT   213.55 (-0.32%)
FB   279.87 (-0.70%)
GOOGL   1,822.78 (+0.05%)
AMZN   3,163.44 (-0.73%)
TSLA   594.78 (+0.24%)
NVDA   539.33 (+0.65%)
BABA   267.61 (+0.26%)
CGC   28.65 (+0.07%)
GE   10.79 (+1.79%)
MU   73.05 (+4.51%)
AMD   93.92 (+1.74%)
T   29.46 (+0.79%)
NIO   42.81 (-5.60%)
F   9.32 (+1.19%)
ACB   10.92 (-2.85%)
BA   232.36 (-2.04%)
NFLX   498.78 (+0.25%)
GILD   61.44 (+0.95%)
DIS   153.83 (+0.39%)
S&P 500   3,692.39 (+0.70%)
DOW   30,165.19 (+0.65%)
QQQ   304.95 (+0.22%)
AAPL   121.97 (-0.79%)
MSFT   213.55 (-0.32%)
FB   279.87 (-0.70%)
GOOGL   1,822.78 (+0.05%)
AMZN   3,163.44 (-0.73%)
TSLA   594.78 (+0.24%)
NVDA   539.33 (+0.65%)
BABA   267.61 (+0.26%)
CGC   28.65 (+0.07%)
GE   10.79 (+1.79%)
MU   73.05 (+4.51%)
AMD   93.92 (+1.74%)
T   29.46 (+0.79%)
NIO   42.81 (-5.60%)
F   9.32 (+1.19%)
ACB   10.92 (-2.85%)
BA   232.36 (-2.04%)
NFLX   498.78 (+0.25%)
GILD   61.44 (+0.95%)
DIS   153.83 (+0.39%)
S&P 500   3,692.39 (+0.70%)
DOW   30,165.19 (+0.65%)
QQQ   304.95 (+0.22%)
AAPL   121.97 (-0.79%)
MSFT   213.55 (-0.32%)
FB   279.87 (-0.70%)
GOOGL   1,822.78 (+0.05%)
AMZN   3,163.44 (-0.73%)
TSLA   594.78 (+0.24%)
NVDA   539.33 (+0.65%)
BABA   267.61 (+0.26%)
CGC   28.65 (+0.07%)
GE   10.79 (+1.79%)
MU   73.05 (+4.51%)
AMD   93.92 (+1.74%)
T   29.46 (+0.79%)
NIO   42.81 (-5.60%)
F   9.32 (+1.19%)
ACB   10.92 (-2.85%)
BA   232.36 (-2.04%)
NFLX   498.78 (+0.25%)
GILD   61.44 (+0.95%)
DIS   153.83 (+0.39%)
Log in
CVE:IPA

ImmunoPrecise Antibodies Ltd. (IPA.V) Stock Forecast, Price & News

C$9.44
-0.25 (-2.58 %)
(As of 12/4/2020 03:34 PM ET)
Add
Compare
Today's Range
C$9.25
Now: C$9.44
C$9.90
50-Day Range
C$1.61
MA: C$3.68
C$10.26
52-Week Range
C$2.50
Now: C$9.44
C$15.70
Volume47,328 shs
Average Volume62,935 shs
Market CapitalizationC$158.23 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; affinity measurements, functional assays, and epitope mapping and binning; and modeling, design, and manufacturing of custom antigen. The company has a collaboration with University of Victoria to develop a saliva-based antibody-based test for the detection and screening of COVID-19; and a research collaboration with Zymeworks Inc. for the development of multiple antibody candidates to fight COVID-19. ImmunoPrecise Antibodies Ltd. was founded in 1989 and is headquartered in Fargo, North Dakota.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.38 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-604-8060626
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$15.11 million
Cash FlowC$0.36 per share
Book ValueC$1.34 per share

Profitability

Miscellaneous

Market CapC$158.23 million
Next Earnings Date12/15/2020 (Estimated)
OptionableNot Optionable
C$9.44
-0.25 (-2.58 %)
(As of 12/4/2020 03:34 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IPA News and Ratings via Email

Sign-up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ImmunoPrecise Antibodies Ltd. (IPA.V) (CVE:IPA) Frequently Asked Questions

How has ImmunoPrecise Antibodies Ltd. (IPA.V)'s stock been impacted by Coronavirus?

ImmunoPrecise Antibodies Ltd. (IPA.V)'s stock was trading at C$0.73 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IPA stock has increased by 1,193.2% and is now trading at C$9.44.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than ImmunoPrecise Antibodies Ltd. (IPA.V)?

Wall Street analysts have given ImmunoPrecise Antibodies Ltd. (IPA.V) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ImmunoPrecise Antibodies Ltd. (IPA.V) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is ImmunoPrecise Antibodies Ltd. (IPA.V)'s next earnings date?

ImmunoPrecise Antibodies Ltd. (IPA.V) is scheduled to release its next quarterly earnings announcement on Tuesday, December 15th 2020.
View our earnings forecast for ImmunoPrecise Antibodies Ltd. (IPA.V)
.

How were ImmunoPrecise Antibodies Ltd. (IPA.V)'s earnings last quarter?

ImmunoPrecise Antibodies Ltd. (IPA.V) (CVE:IPA) posted its quarterly earnings results on Tuesday, September, 29th. The company reported ($0.01) earnings per share (EPS) for the quarter. The business earned $3.77 million during the quarter.
View ImmunoPrecise Antibodies Ltd. (IPA.V)'s earnings history
.

Who are some of ImmunoPrecise Antibodies Ltd. (IPA.V)'s key competitors?

What other stocks do shareholders of ImmunoPrecise Antibodies Ltd. (IPA.V) own?

Who are ImmunoPrecise Antibodies Ltd. (IPA.V)'s key executives?

ImmunoPrecise Antibodies Ltd. (IPA.V)'s management team includes the following people:
  • Dr. James S. Kuo M.B.A., M.D., Independent Chairman (Age 55)
  • Dr. Jennifer Lynne Bath Ph.D., CEO, Pres & Director
  • Ms. Lisa Helbling, Chief Financial Officer
  • Mr. David E. Orton, Chief Operating Officer
  • Dr. Yasmina Noubia Abdiche Ph.D., Chief Scientific Officer
  • Ms. Lauren Smith, VP of Marketing and Sales
  • Dr. Stefan Lang, Chief Bus. Officer

What is ImmunoPrecise Antibodies Ltd. (IPA.V)'s stock symbol?

ImmunoPrecise Antibodies Ltd. (IPA.V) trades on the Canadian Venture Exchange (CVE) under the ticker symbol "IPA."

How do I buy shares of ImmunoPrecise Antibodies Ltd. (IPA.V)?

Shares of IPA and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is ImmunoPrecise Antibodies Ltd. (IPA.V)'s stock price today?

One share of IPA stock can currently be purchased for approximately C$9.44.

How big of a company is ImmunoPrecise Antibodies Ltd. (IPA.V)?

ImmunoPrecise Antibodies Ltd. (IPA.V) has a market capitalization of C$158.23 million and generates C$15.11 million in revenue each year.

What is ImmunoPrecise Antibodies Ltd. (IPA.V)'s official website?

The official website for ImmunoPrecise Antibodies Ltd. (IPA.V) is immunoprecise.com.

How can I contact ImmunoPrecise Antibodies Ltd. (IPA.V)?

ImmunoPrecise Antibodies Ltd. (IPA.V)'s mailing address is 880-580 Hornby St, VANCOUVER, BC V6C 3B6, Canada. The company can be reached via phone at +1-604-8060626.

This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.